Literature DB >> 19235102

Screening for premutation in the FMR1 gene in male patients suspected of spinocerebellar ataxia.

Marta Rajkiewicz1, Anna Sułek-Piatkowska, Wioletta Krysa, Elzbieta Zdzienicka, Walentyna Szirkowiec, Jacek Zaremba.   

Abstract

BACKGROUND AND
PURPOSE: The aim of this study was to determine the molecular basis of the disorder in patients suspected of spinocerebellar ataxias (SCAs) and search for premutation in the FMR1 gene causing FXTAS among patients in whom 9 SCA types were previously excluded.
MATERIAL AND METHODS: DNA obtained from 1385 patients suspected of SCA and 516 controls were used for molecular tests. DNA analysis was carried out by PCR reaction with specific primers. PCR products were separated in denaturing polyacrylamide gels in an ABIPrism 377 sequencer. Amplification of polymorphic regions embracing trinucleotide repeats was performed in the following genes: ATXN1 (SCA1), ATXN2 (SCA2), ATXN3 (SCA3), CACNA1A (SCA6), ATXN7 (SCA7), ATXN80S (SCA8), PPP2R2B (SCA12), TBP (SCA17), ATN1 (DRPLA). Afterwards, a search for FXTAS caused by premutation in the FMR1 gene was performed. Two hundred and sixty-nine subjects selected from the study group with 9 excluded types of SCAs were tested; a subgroup of 178 males aged 50 years was sorted out.
RESULTS: Molecular analysis in 1385 individuals revealed SCA1 in 225, SCA2 in 56, SCA8 in 33, SCA17 in 4 subjects. SCA3, SCA6, SCA7, SCA12, and DRPLA were not detected. Within the subgroup aged>or=50 years with ataxia in whom 9 types of SCAs were excluded only one case of FXTAS was detected, which is 1/178 (0.56%), and within the group of males>or=70 years (n=19) one case was also found (5.26%).
CONCLUSIONS: The low frequency of FXTAS in the studied material probably results from the fact that the syndrome is much more common in elderly persons (penetrance of the pathogenic premutation gene is higher among elderly individuals).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19235102

Source DB:  PubMed          Journal:  Neurol Neurochir Pol        ISSN: 0028-3843            Impact factor:   1.621


  6 in total

Review 1.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

Review 2.  Fragile X-associated tremor/ataxia syndrome.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Ann N Y Acad Sci       Date:  2015-01-26       Impact factor: 5.691

3.  Fragile x-associated tremor ataxia syndrome: the expanding clinical picture, pathophysiology, epidemiology, and update on treatment.

Authors:  Deborah A Hall; Joan A O'keefe
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-05-11

4.  FXTAS is rare among Portuguese patients with movement disorders: FMR1 premutations may be associated with a wider spectrum of phenotypes.

Authors:  Ana I Seixas; José Vale; Paula Jorge; Isabel Marques; Rosário Santos; Isabel Alonso; Ana M Fortuna; Jorge Pinto-Basto; Paula Coutinho; Russell L Margolis; Jorge Sequeiros; Isabel Silveira
Journal:  Behav Brain Funct       Date:  2011-06-03       Impact factor: 3.759

5.  Towards a Better Molecular Diagnosis of FMR1-Related Disorders-A Multiyear Experience from a Reference Lab.

Authors:  Sylwia Olimpia Rzońca; Monika Gos; Daniel Szopa; Danuta Sielska-Rotblum; Aleksandra Landowska; Agnieszka Szpecht-Potocka; Michał Milewski; Jolanta Czekajska; Anna Abramowicz; Ewa Obersztyn; Dorota Maciejko; Tadeusz Mazurczak; Jerzy Bal
Journal:  Genes (Basel)       Date:  2016-09-02       Impact factor: 4.096

6.  Prevalence of Fragile X-Associated Tremor/Ataxia Syndrome in Patients with Cerebellar Ataxia in Japan.

Authors:  Yujiro Higuchi; Masahiro Ando; Akiko Yoshimura; Satoshi Hakotani; Yuki Koba; Yusuke Sakiyama; Yu Hiramatsu; Yuichi Tashiro; Yoshimitsu Maki; Akihiro Hashiguchi; Junhui Yuan; Yuji Okamoto; Eiji Matsuura; Hiroshi Takashima
Journal:  Cerebellum       Date:  2021-09-09       Impact factor: 3.648

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.